Led by a visionary leadership team with extensive experience in top global biopharmaceutical companies, Hyperway currently has a size of over 100 employees, composed of elite young blood, mostly in their vigorous 30s, with expertise in various areas of drug discovery and development.
In Hyperway, we are insightful in selecting targets of novelty, druggability, and unmet clinical need, we are creative and sophisticated in designing drugs of proprietary value, we are proficient in advancing leads of efficacy and safety, we are competent in delivering CMC products of quality, and we are efficient in executing clinical development plans of thoroughness.
Hyperway is dedicated to developing First-In-Class and/or Best-In-Class small molecule drugs across cancer, pain, and autoimmune diseases. Hyperway has strategically staged our projects so that our portfolio is well-positioned with compounds in various phases of drug discovery and development to ensure a sustainable pipeline.
With our strength in designing brain-penetrant small-molecule drugs, Hyperway aims to provide the cure for those CNS-related diseases that remain in large medical needs. This platform has quickly contributed to our drug pipelines。 Hyperway is seeking partners, in China and/or abroad, to jointly develop innovative medicines.